



T: 49.69.74220.152  
lukas.greilich@skadden.com

## Education

Second State Exam, Higher Regional Court of Frankfurt am Main, 2015

LL.M., The University of Sheffield, 2013

First State Exam, Humboldt University of Berlin, 2012

## Bar Admissions

Frankfurt am Main

Lukas Greilich focuses his practice on advising issuers, shareholders and underwriters on international equity capital markets transactions, including on equity-linked issuances, as well as general securities-related matters.

Mr. Greilich has significant experience in capital markets transactions, representing issuers, shareholders and underwriters in connection with initial public offerings, capital increases, rights offerings, block trades, and offerings of convertible and hybrid capital instruments. His practice also includes capital markets-related regulatory advice. In recognition of his work, Mr. Greilich has been repeatedly named to *Best Lawyers* (including its 2026 edition) in addition to being recently honored as a Rising Star in Capital Markets by *IFLR1000*. His recent significant representations include advising:

### Capital Markets (Equity)

- Euronext Brussels and Euronext Amsterdam-listed **ONWARD Medical**, a leading developer of spinal cord injury therapies, on:
  - a cash capital increase of more than €50 million
  - a €50 million cash capital increase and cornerstone investment by Ottobock SE & Co. KGaA
  - a €52.5 million debt financing from U.S. lender Runway Growth Finance
- HSBC, Morgan Stanley and UBS (acting as joint global coordinators for a banking syndicate) as international underwriters' counsel in connection with the 775 million Swiss franc rights offering of **ams OSRAM**
- **FINN**, a leading car subscription platform, on its US\$110 million Series B financing round led by Korelya Capital, including both new and existing investors, with an implied company value of more than US\$500 million
- Berenberg Capital Markets LLC and Craig-Hallum Capital Group LLC as underwriters on the proposed IPO of common shares and listing on Nasdaq of **Sono Group N.V.**
- Morgan Stanley and UBS as joint global coordinators and joint bookrunners in connection with a capital increase of **Bachem Holding AG**
- the joint bookrunners, including Deutsche Bank and J.P. Morgan, on the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of **ABOUT YOU Holding AG**
- Bank of America, Morgan Stanley and UBS on the €2.3 billion initial public offering of ordinary shares of **Vantage Towers AG** on the Frankfurt Stock Exchange
- Jefferies and BofA Securities as joint global coordinators and joint bookrunners in connection with capital increases of **Zur Rose Group AG**

### Capital Markets (Equity-Linked/Debt)

- HSBC in connection with the partial repurchase offer by **ams OSRAM** for up to €300 million (US\$353 million) of its convertible bonds due 2027
- AI company **Baidu, Inc.** on its \$2 billion offering of zero-coupon exchangeable bonds due 2032. The bonds were listed on the Frankfurt Stock Exchange's open market segment
- banks on the €200 million senior notes offering of **ams OSRAM**
- **ONWARD Medical** in connection with a loan agreement

- 
- Deutsche Bank, HSBC, UBS, COMMERZBANK and UniCredit in connection with the issuance of senior unsecured notes in the aggregate principal amount of €1 billion by **ams OSRAM**
  - **AGRAVIS Raiffeisen AG** on multiple issuances of participation rights
  - UBS and HSBC as global coordinators in connection with the €650 million and US\$400 million senior notes offering of **ams AG** and the subsequent tap offering of €200 million and US\$50 million

## Mergers and Acquisitions

- **Exact Sciences** on its \$23 billion acquisition by Abbott Laboratories
- **MorphoSys AG** in its €2.7 billion sale to, and public takeover by, Novartis and the simultaneous disposition of the worldwide marketing rights of its antibody drug Monjuvi to Incyte Corporation
- **CureVac N.V.** on its all-stock acquisition by BioNTech SE that values CureVac N.V. at US\$1.25 billion
- the management and supervisory boards of **Fresenius** on the company's exit from the Austrian and international businesses of VAMED AG
- **phenox** and its shareholders, including health care private equity investor **SHS**, on the sale of phenox to Wallaby Medical for a total consideration of €500 million including milestone payments
- **Armira** and **Boxine** on Boxine's €1 billion business combination with 468 SPAC I SE, one of the first de-SPAC transactions in the market involving a German-listed blanc cheque company
- **SIGNA Sports United GmbH** in connection with its US\$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group

Mr. Greilich's representations prior to joining Skadden include advising:

- Goldman Sachs International, Morgan Stanley and Berenberg on the IPO of **Global Fashion Group S.A.**
- **Siemens Healthineers AG** on its IPO on the Frankfurt Stock Exchange
- Berenberg and ODDO BHF on the IPO of **Dermapharm Holding SE** on the Frankfurt Stock Exchange
- Deutsche Bank, J.P. Morgan, Morgan Stanley, Berenberg, BNP Paribas and Rabobank on the IPO of **HelloFresh SE** on the Frankfurt Stock Exchange
- ZF Friedrichshafen AG on the sale of a stake in **Haldex A/B** by way of an accelerated book building offering to institutional investors